ImClone Investigational Site

Charleston, South Carolina 29425

0 studies enrolling now · 6 studies all time

What they study most

Adenocarcinoma, Breast Cancer, Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Metastatic Pancreatic Cancer, Sarcoma, Soft Tissue

Studies at this site

• Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma — Completed
• A Study of Olaratumab in Soft Tissue Sarcoma — Completed
• A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer — Completed
• A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib — Completed
• Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer — Stopped early
• Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer — Completed